Almonty Industries Inc ALM

Laboratorios Almirall SA is a dermatology prescription drug company with a direct presence in 21 countries through 13 affiliates. The company employs more than 1,800 people around the world. Almirall is considered the top dermatology prescription drug company in Germany, the 3rd in Europe, and the 4th in the US.

The company is focused on developing a range of dermatology solutions treating psoriasis, acne, androgenic alopecia, atopic dermatitis, actinic keratosis, non-melanoma cell cancer, pruritus, rare diseases, and more. Other therapeutic divisions include CNS (central nervous system), cardiovascular, and gastrointestinal.

The company is heavily focused on research and development. Approximately 15% of its total workforce is focused on R&D and in 2018, 11.6% of its net sales were dedicated to R&D. That same year, Almirall received EMA approval and rollout of its first biologic treatment, ILUMETRI® for moderate-to-severe plaque psoriasis, announced the EU rollout of Skilarence® for moderate-to-severe plaque psoriasis, and received FDA approval of SeysaraTM, a new oral antibiotic for treating acne vulgaris.

During the first half of fiscal 2019, the company reported a 16% growth in net sales to €430.3 million and total revenue of €469 million. Diversify your portfolio and buy ALM stocks.